ISRG
Earnings were good. The vibes? Less so.
Intuitive Surgical came out swinging with a better-than-expected second quarter, posting $2.80 a share on $2.89 billion in revenue. That topped estimates, which is usually the part where the stock pops and everyone nods solemnly at the spreadsheet gods.
Instead, shares slid 11.1% to $357.76 in premarket trading. Why? Because the market is a drama queen, and analysts also decided to take a little air out of the balloon after the print.
The analyst plot twist
Two firms moved their price targets lower even while keeping their overall bullish stance:
- BTIG’s Ryan Zimmerman kept a Buy rating but cut the target from $512 to $469
- Baird’s David Rescott kept an Outperform rating and trimmed the target from $525 to $500
That’s not exactly a vote of no confidence. But it is Wall Street’s way of saying, “Nice quarter. We’re just less excited than we were 24 hours ago.”
Why investors should care
Intuitive is still leaning on its robot-surgery franchise — da Vinci, Ion, and its digital tools — to keep the growth story alive. But when a company beats estimates and the stock still drops double digits, you’re usually looking at a market that wanted not just a good quarter, but a great excuse to pay up.
Big picture: Intuitive is still executing, but the bar for this kind of premium healthcare tech stock remains sky-high. And when expectations are wearing stilts, even a clean beat can feel like a stumble.